8 results
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…
The aim of this study is to investigate the overnight effect of a single bout of NMES on muscle protein synthesis rates in healthy elderly males.
The aim of this study is to investigate the effect of a single bout of NMES on post-prandial muscle protein accretion during the day and prior to sleep in healthy elderly males.
The purpose of this project is to evaluate the combination of ER using the multi-band mucosectomy technique and RFA (HALO360/HALO90) for treatment of Barrett*s esophagus with HGD or early cancer. This will be a multi-centre European study including…
1. The primary objective of this phase I/II clinical trial is to evaluate the safety and toxicity of ACT plus nivolumab according to CTCAE 4.0 criteria. Toxicity grade 3 or less and SAE related to treatment but that does not result in treatment…
In this study we will look at the blood levels of the study compound ziltivekimab. We will investigate how quickly and to what extent different compositions of ziltivekimab are absorbed, transported, and eliminated from the body. Ziltivekimab is not…
The primary objective is to demonstrate the superiority of ziltivekimab 15 mg s.c. once-monthly in reducing the risk of MACE (as defined by the primary endpoint) compared to placebo, both added to standard of care, in participants with established…
To study whether ziltivekimab therapy reduces arterial wall inflammation as assessed by imaging, and reduces the systemic inflammatory tone as assessed by circulating monocytes, inflammatory biomarkers and proteomics.